



CORRECTION

Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

Pietro Lampertico · Stefan Mauss · Marcello Persico ·
Stephen T. Barclay · Steven Marx · Kristina Lohmann ·
Mark Bondin · ZhenZhen Zhang · Fiona Marra · Pamela S. Belperio ·
Heiner Wedemeyer · Steven Flamm

Published online: September 11, 2020
© The Author(s) 2020

Correction to: Adv Ther (2020) 37:4033–4042
<https://doi.org/10.1007/s12325-020-01449-0>

In the original article, there is an error in Fig. 1.
The correct Fig. 1 is given below:

The original article can be found online at <https://doi.org/10.1007/s12325-020-01449-0>.

P. Lampertico (✉)
Division of Gastroenterology and Hepatology, CRC
“A.M. and A.Migliavacca” Center for Liver Disease,
Foundation IRCCS Ca’ Granda Ospedale Maggiore
Policlinico, Milan, Italy
e-mail: pietro.lampertico@unimi.it

P. Lampertico
Department of Pathophysiology and
Transplantation, University of Milan, Milan, Italy

S. Mauss
Center for HIV and Hepatogastroenterology,
Düsseldorf, Germany

M. Persico
Internal Medicine and Hepatology Unit, University
of Salerno, Salerno, Italy

S. T. Barclay
Department of Life Sciences, Glasgow Caledonian
University, Glasgow, UK

S. T. Barclay
Gastroenterology, Glasgow Royal Infirmary,
Glasgow, UK

S. Marx · M. Bondin · Z. Zhang
AbbVie Inc., North Chicago, IL, USA

K. Lohmann
AbbVie Deutschland GmbH Co. KG, Wiesbaden,
Germany

F. Marra
University of Liverpool Hepatology Drug
Interactions Group, Liverpool, UK

P. S. Belperio
Department of Veterans Affairs, VA Palo Alto
Healthcare System, Palo Alto, CA, USA

H. Wedemeyer
Department of Gastroenterology and Hepatology,
Essen University Hospital, Essen, Germany




Fig. 1 SVR12 rates in TN patients with CC, GT1–6^a treated with 8 weeks of G/P. ^aScottish HCV study included GT1,2,4–6, US VA study included GT1–3. ^bFour patients were lost to follow-up in the ITT population. ^cOne confirmed reinfection with subsequent spontaneous clearance, no virologic failure. ^dOne virologic failure. ^eOne patient died after completing treatment but before SVR12 testing, one patient was lost to follow-up.

^fPatients missing SVR12 data were excluded from SVR12 analysis. *CC* compensated cirrhosis, *DHC-R* German Hepatitis C-Registry, *G/P* glecaprevir/pibrentasvir, *GT* genotype, *HCV* hepatitis C virus, *ITT* intention-to-treat, *PMOS* post-marketing observational studies, *SVR12* sustained virologic response at week 12, *TN* treatment-naïve, *VA* Veterans Association

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide

H. Wedemeyer
Leberstiftungs-GmbH Deutschland, Hannover,
Germany

H. Wedemeyer
Department of Gastroenterology, Hepatology and
Endocrinology, Hannover Medical School,
Hannover, Germany

S. Flamm
Northwestern University Feinberg School of
Medicine, Chicago, IL, USA

a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.